FLXN - フレキシオン・セラピュ―ティクス (Flexion Therapeutics Inc.) フレキシオン・セラピュ―ティクス

 FLXNのチャート


 FLXNの企業情報

symbol FLXN
会社名 Flexion Therapeutics Inc. (フレキシオン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 フレキシオン・セラピュティクス(Flexion Therapeutics Inc.)は米国の専門製薬会社である。同社は変形性関節症の一種である変形性関節症(OA)で始まる筋骨格系の患者の治療用の現地療法の開発・商品化に従事する。主要製品候補Zilrettaは、後期の、注射可能な、徐放性の、関節内(IA)の治験用ステロイドである。同社は中等度から重度のOA膝痛患者の治療としてZilrettaを開発している。同社はステロイド、トリアムシノロンアセトニド(TCA)とポリ乳酸-co-グリコール酸(PLGA)を組み合わせて、関節内に持続的な治療濃度を与え、持続的な鎮痛効果をもたらすようにZilrettaを設計した。他の製品候補には、術後疼痛のためのFX007と、末期のOA患者の治療のためのFX005が含まれる。同社はZilrettaの第II相臨床試験を実施している。   フレキシオン・セラピュ―ティクスは米国の製薬会社。注射による疼痛治療薬の開発と商業化に従事。変形性関節症、退行性関節炎、及び術後疼痛などの筋骨格の抗炎症及び鎮痛治療を対象とする。主な臨床中の製品候補には、中等から重度の変形性関節症による疼痛のステロイド治療薬「FX006」がある。本社はマサチュ―セッツ州。   
本社所在地 10 Mall Road Suite 301 Burlington MA 01803 USA
代表者氏名 Patrick J. Mahaffy Patrick J. Mahaffy
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 781-305-7777
設立年月日 39387
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 251人
url www.flexiontherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/flxn
adr_tso
EBITDA EBITDA(百万ドル) -156.95000
終値(lastsale) 18.64
時価総額(marketcap) 704882336.64
時価総額 時価総額(百万ドル) 716.22700
売上高 売上高(百万ドル) 6.34600
企業価値(EV) 企業価値(EV)(百万ドル) 534.98700
当期純利益 当期純利益(百万ドル) -170.16000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Flexion Therapeutics Inc revenues increased from $0K to $6M. Net loss increased 62% to $85.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General_admn exp increase from $25.2M to $52.6M (expense) Interest Expense increase from $3.5M to $7.8M (expense).

 FLXNのテクニカル分析


 FLXNのニュース

   Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conference  2021/03/15 13:00:00 Yahoo Finance
BURLINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference. The virtual fireside chat is scheduled to begin at 10:00 a.m. ET on Wednesday, March 17, 2021. To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com. About Flexion TherapeuticsFlexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun. Please visit flexiontherapeutics.com. Contact: Scott YoungVice President, Corporate Communications & Investor RelationsFlexion Therapeutics, Inc.
   Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results  2021/03/10 21:01:00 GlobeNewswire
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $85.6 million for full-year 2020 representing 17%…
   Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery  2021/03/01 12:58:00 Benzinga
The FDA signed off Flexion Therapeutics Inc's (NASDAQ: FLXN) Phase 1b proof of concept trial evaluating FX301 administered as a …
   Flexion Therapeutics, Inc. (NASDAQ:FLXN) Insider Sells $32,931.20 in Stock  2021/01/30 02:24:41 Watchlist News
Flexion Therapeutics, Inc. (NASDAQ:FLXN) insider Melissa Layman sold 2,624 shares of the business’s stock in a transaction on Thursday, January 28th. The stock was sold at an average price of $12.55, for a total value of $32,931.20. Following the completion of the sale, the insider now directly owns 91,000 shares in the company, valued at […]
   Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference  2021/01/07 21:30:00 GlobeNewswire
BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and…
   Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference  2021/01/07 21:30:00 GlobeNewswire
BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and…
   Joint Pain Injection Market With Top Key Players like Sanofi-aventis U.S. LLC, a Sanofi Company, Pnika Therapeutics, Chugai Pharmaceutical Co., Ltd, Ferring B.V, Biovefizer, Antus Fidia Pharma USA, Zimmer Biomet Holdings, Flexion Therapeutics, Seikagaku C  2020/11/23 07:37:44 OpenPR
Joint pain injections are medicinal fluids inserted in the body of patients to get faster relief from severe pain. The joint pain injections are used to reduce inflammation in the joints. There are several types of injections available in the
   Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights  2020/11/04 21:01:00 GlobeNewswire
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7 million in third quarter 2020 BURLINGTON,…
   Flexion Therapeutics (NASDAQ:FLXN) Rating Lowered to Hold at Zacks Investment Research  2020/10/24 03:00:44 Stock Observer
Zacks Investment Research cut shares of Flexion Therapeutics (NASDAQ:FLXN) from a buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and […]
   Flexion Therapeutics (NASDAQ:FLXN) Downgraded by Zacks Investment Research  2020/10/22 05:08:43 Dakota Financial News
Flexion Therapeutics (NASDAQ:FLXN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports. According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic […]
   Joint Pain Injection Market With Top Key Players like Sanofi-aventis U.S. LLC, a Sanofi Company, Pnika Therapeutics, Chugai Pharmaceutical Co., Ltd, Ferring B.V, Biovefizer, Antus Fidia Pharma USA, Zimmer Biomet Holdings, Flexion Therapeutics, Seikagaku C  2020/11/23 07:37:44 OpenPR
Joint pain injections are medicinal fluids inserted in the body of patients to get faster relief from severe pain. The joint pain injections are used to reduce inflammation in the joints. There are several types of injections available in the
   Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights  2020/11/04 21:01:00 GlobeNewswire
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7 million in third quarter 2020 BURLINGTON,…
   Flexion Therapeutics (NASDAQ:FLXN) Rating Lowered to Hold at Zacks Investment Research  2020/10/24 03:00:44 Stock Observer
Zacks Investment Research cut shares of Flexion Therapeutics (NASDAQ:FLXN) from a buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and […]
   Flexion Therapeutics (NASDAQ:FLXN) Downgraded by Zacks Investment Research  2020/10/22 05:08:43 Dakota Financial News
Flexion Therapeutics (NASDAQ:FLXN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports. According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic […]
   Flexion Therapeutics (NASDAQ:FLXN) Upgraded at Zacks Investment Research  2020/10/20 05:38:41 Transcript Daily
Zacks Investment Research upgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a hold rating to a buy rating in a report published on Friday morning, Zacks.com reports. The firm currently has $15.00 price objective on the specialty pharmaceutical company’s stock. According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 フレキシオン・セラピュ―ティクス FLXN Flexion Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)